Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2021-05-28
Target enrollment:
Participant gender:
Summary
This is a Phase I, non-randomized, open-label, multiple dose study of pexidartinib in Asian
subjects with advanced solid tumors. The study will be conducted in a dose escalation to
assess the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD), and
preliminary antitumor activity of pexidartinib.